Boreal Genomics nets $18 Million in Series C funding
Boreal Genomics Inc, a provider of technology for non-invasive genomic profiling of tumors from blood plasma of cancer patients, has received US$18 million in Series C financing. The round included existing investors ARCH Venture Partners and Kearny Venture Partners, as well as undisclosed new strategic and private investors. The company, which has offices in Vancouver and Los Altos, Calif., will use the new funds to expand commercial operations in the translational research market, scale laboratory capabilities and launch clinical applications. Founded in 2007, Boreal has been venture-backed since 2010.
15 October 2013•3 mins read
